Ipsen took several major steps forward in North America during 2015. The Group launched Somatuline® for neuroendocrine tumors in Canada and the United States as well as Dysport® in adult upper limb spasticity. These milestones allowed Ipsen Biopharmaceuticals to achieve profitability 18 months ahead of plan.
2015 also marked the inauguration of the new Ipsen Bioscience R&D facility in Cambridge (Massachussets), a top biopharma hub where Ipsen researchers work on the discovery and development of highly differentiated therapeutic peptides that address unmet medical needs in endocrinology and oncology.
Ipsen
worldwide
North America
SPAIN
Despite a challenging environment, Ipsen posted double-digit sales growth in Spain thanks to Somatuline®, which became a market leader in 2015, and a stronger market share for Decapeptyl®, driven by a robust promotional effort by the sales team. In January 2015, Ipsen Pharma set up the “Iberia cluster” formed of Spain and Portugal to maximize synergies, efficiency and team collaboration.
Since its creation in 1988, Ipsen Pharma has established an excellent reputation and high value relationships in Spain during the last years based on a combination of patient focus, best-in class products and strong scientific approach.
Since its creation in 1988, Ipsen Pharma has established an excellent reputation and high value relationships in Spain during the last years based on a combination of patient focus, best-in class products and strong scientific approach.
SPAIN
Despite a challenging environment, Ipsen posted double-digit sales growth in Spain thanks to Somatuline®, which became a market leader in 2015, and a stronger market share for Decapeptyl®, driven by a robust promotional effort by the sales team. In January 2015, Ipsen Pharma set up the “Iberia cluster” formed of Spain and Portugal to maximize synergies, efficiency and team collaboration.
Since its creation in 1988, Ipsen Pharma has established an excellent reputation and high value relationships in Spain during the last years based on a combination of patient focus, best-in class products and strong scientific approach.
Since its creation in 1988, Ipsen Pharma has established an excellent reputation and high value relationships in Spain during the last years based on a combination of patient focus, best-in class products and strong scientific approach.
AUSTRALIA
Ipsen has been present in Australia since 2001 and currently employs more than 50 people. The Group achieved a significant milestone in 2015 with the GEP-NET launch of Somatuline®, which is now the market leader in three Australian states and has achieved a total market share of 39.5% in the country. Ipsen’s strength in Australia (and also New Zealand) is a combination of dedicated staff and vision. The passion of its dedicated staff is to improve the lives of patients with the aim of becoming a leader in oncology.